Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by digger144on Jan 07, 2013 8:57pm
289 Views
Post# 20808060

West Side Story...Coming Together..

West Side Story...Coming Together..

22,672 ounces...we are headed in the right direction!

However...the milling through-put did not match Q3 numbers, which brought in a shortfall of 657 ounces...seems that there is always an issue....somewhat disappointing.

Q3...2075 tonnes per day

Q4...2019 tonnes per day

Shortfall of 56 tonnes per day.

56 X 90 days (quarter) = 5040 tonnes

5040 X 4.04 grams per tonne = 20,361 grams divided by 31 g (troy ounce) = 657 ounces.

The Underground Production is most definitely the highlight and of which the market has and will be focusing on moving forward.  My estimate puts the Underground Production at about 700 tonnes per day @ 6.00 g/t.  Q3 production was about 475 t.p.d.

Not knowing the factual numbers I can only speculate using Q3 numbers...the Open Pit grade was at 2.55 g.t. and the Underground at 6.00 g.t.

The important fact is that there is no doubt that the Underground high-grade production is increasing steadily and if this continues they should be in full production before the current quarter is completed...Nice!

The average grade of 4.04 g.t. in Q4 is a major improvement from Q3 @ 3.34 g.t....we should be rewarded accordingly moving forward.  The goal of 25,000 ounces per quarter is within reach!

The break-out is at $1.05...selling has always come in at this price...perhaps this will change soon....I will most definitely be buying if this is breached.

All in all...quite positive...let us await the market reaction in the next couple of days!

All the Best!

Digger144

P.S.  The addition of Daniel Racine was most definitely the right move, along with other placements in recent history.  A nice chapter has closed...the story is building momentum with factual numbers being posted!  The market will get it soon!

 

Bullboard Posts